Nobivac Bb for Cats
Recent research into respiratory disease in cats has identified a bacterium, called Bordetella bronchiseptica, that is increasingly being recognised as a risk to the cat population, particularly those in multicat environments including boarding and breeding catteries and rescue shelters. In addition contact with dogs can also lead to infection with Bordetella bronchiseptica. Nobivac Bb for Cats is licensed for the active immunisation of cats, of 1 month of age or older, to reduce clinical signs of Bordetella bronchiseptica associated upper respiratory tract disease. Nobivac Bb may only be prescribed by your veterinary surgeon from whom advice should be sought. Further information is available on request.
Contains at least 106.3 cfu live Bordetella bronchiseptica strain B-C2, per 0.2 ml dose of reconstituted suspension.
For active immunisation of cats, of 1 month of age or older, to reduce clinical signs of Bordetella bronchiseptica associated upper respiratory tract disease.
Dosage and administration
One dose, of 0.2 ml of reconstituted vaccine at least 72 hours prior to period of anticipated risk. For intra-nasal administration.
Allow the solvent to reach room temperature (15 - 25°C). Aseptically reconstitute the freeze-dried vaccine with 0.3 ml of the sterile solvent provided. Shake well after addition of the solvent. Withdraw 0.2 ml of reconstituted vaccine into an appropriate syringe, remove the needle and administer the complete contents of the syringe into one of the cat’s nostrils.
Advice on correct administration
The head of the cat should be held with the nose pointing upward and the mouth closed, so that it is forced to breathe through its nostrils. Place the syringe in front of one of the nostrils and carefully administer the whole contents of the syringe into the nasal cavity via this nostril. The vaccine is administered directly from the tip of the syringe onto the opening of the nostril and enters the nasal cavity during inhalation.
Contra-indications, warnings, etc
Do not use in pregnant or lactating queens.
Sneezing, coughing, mild and transient discharge from the eyes or nose may occasionally occur. After overdose, identical signs appear particularly in very young susceptible kittens. In animals, which show more severe signs, appropriate antibiotic treatment may be indicated.
Only healthy cats should be vaccinated.
Sneezing by cats after administration does not adversely affect the efficacy of the product.
Do not mix with any other product except the solvent supplied for use with the vaccine.
Do not administer during antibiotic treatment, or in conjunction with any other intranasal product.
If any antibiotic is administered within one week after vaccination, the vaccination should be repeated after the antibiotic treatment has been completed.
Vaccinated animals can spread the Bordetella bronchiseptica vaccine strain for six weeks; in individual cases for at least one year. Intermittent spreading is also possible.
Although the risk of immunocompromised humans becoming infected with Bordetella bronchiseptica is extremely low, it is advised that cats that are in close contact with immunocompromised humans are not vaccinated with this vaccine. Such individuals should also be made aware that cats can shed the organism for up to 1 year after vaccination.
Dogs, pigs and unvaccinated cats may react to the vaccine strain with mild and transient respiratory signs. Other animals, such as rabbits and small rodents, have not been tested.
Appropriate disinfection procedures should be used following use of this live bacterial vaccine e.g. in cases of accidental spillage.
In case of accidental self-administration seek medical advice immediately and show the package insert or the label to the physician.
For animal treatment only. Keep out of reach of children.
Store at +2°C to +8°C. Protect from light.
Dispose of waste material that has had contact with the active substance by boiling, incineration or immersion in an appropriate disinfectant approved for use by the competent authorities.
Cartons of 5 single dose vials with solvent.
The onset of immunity was established in 8 week old cats as early as 72 hours after vaccination.
The duration of immunity is up to 1 year.
No information is available on the safety and efficacy from the use of this vaccine with any other. It is therefore recommended that no other vaccine should be administered within 14 days before or after vaccination with the product.
Marketing authorisation number